References
- Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. https://doi.org/10.1002/ijc.29210
- Berghmans T, Paesmans M, Sculier JP. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol 2011;3:127-38. https://doi.org/10.1177/1758834011401951
- Tong YS, Tan J, Zhou XL, Song YQ, Song YJ. Systemic immuneinflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer. J Transl Med 2017;15:221. https://doi.org/10.1186/s12967-017-1326-1
- Vrankar M, Stanic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol 2018;52:281-8. https://doi.org/10.2478/raon-2018-0009
- National Comprehensive Cancer Network. NCCN Guidelines: non-small-cell lung cancer (version 2.2019) [Internet]. Plymouth Meeting, PA: National Comprehensive Cancer Network; c2018 [cited 2019 Aug 21] Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
- Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106:dju124.
- Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014;23:1204-12. https://doi.org/10.1158/1055-9965.EPI-14-0146
- Son SH, Park EY, Park HH, Kay CS, Jang HS. Pre-radiotherapy neutrophil-to-lymphocyte ratio as an independent prognostic factor in patients with locally advanced hepatocellular carcinoma treated with radiotherapy. Oncotarget 2017;8:16964-71. https://doi.org/10.18632/oncotarget.15209
- Sung S, Son SH, Park EY, Kay CS. Prognosis of locally advanced rectal cancer can be predicted more accurately using preand post-chemoradiotherapy neutrophil-lymphocyte ratios in patients who received preoperative chemoradiotherapy. PLoS One 2017;12:e0173955. https://doi.org/10.1371/journal.pone.0173955
- Scilla KA, Bentzen SM, Lam VK, et al. Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist 2017;22:737-42. https://doi.org/10.1634/theoncologist.2016-0443
- Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a metaanalysis. Clinics (Sao Paulo) 2015;70:524-30. https://doi.org/10.6061/clinics/2015(07)10
- Suh KJ, Kim SH, Kim YJ, et al. Post-treatment neutrophil-tolymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother 2018;67:459-70. https://doi.org/10.1007/s00262-017-2092-x
- Kim TG, Park W, Choi DH, et al. Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer. Radiat Oncol J 2017;35:217-26. https://doi.org/10.3857/roj.2017.00269
- Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer 2016;16:431-46. https://doi.org/10.1038/nrc.2016.52
- Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 2006;103:12493-8. https://doi.org/10.1073/pnas.0601807103
- Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-celldependent tumour angiogenesis. Nature 2007;450:825-31. https://doi.org/10.1038/nature06348
- Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7. https://doi.org/10.1038/nature01322
- Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010;30:2362-7. https://doi.org/10.1161/ATVBAHA.110.207514
- Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017;377:1919-29. https://doi.org/10.1056/NEJMoa1709937
- Khunger M, Patil PD, Khunger A, et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PLoS One 2018;13:e0197743. https://doi.org/10.1371/journal.pone.0197743
- Liang SB, Teng JJ, Hu XF, et al. Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy. BMC Cancer 2017;17:506. https://doi.org/10.1186/s12885-017-3480-5
- Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 2013;31:140-4. https://doi.org/10.3109/07357907.2012.762780
- Cannon NA, Meyer J, Iyengar P, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer. J Thorac Oncol 2015;10:280-5. https://doi.org/10.1097/jto.0000000000000399
Cited by
- The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy vol.16, pp.9, 2019, https://doi.org/10.2217/fon-2019-0837
- Clinical Significance of Systemic Inflammation Markers in Newly Diagnosed, Previously Untreated Hepatocellular Carcinoma vol.12, pp.5, 2019, https://doi.org/10.3390/cancers12051300
- Clinical importance of the absolute count of neutrophils, lymphocytes, monocytes, and platelets in newly diagnosed hepatocellular carcinoma vol.11, pp.1, 2019, https://doi.org/10.1038/s41598-021-82177-5